

# Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals

Roberta D'Ambrosio<sup>1</sup>  
Elisabetta Degasperis<sup>1</sup>  
Pietro Lampertico<sup>1,2</sup>

<sup>1</sup>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; <sup>2</sup>CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

**Abstract:** Chronic infection with hepatitis C virus (HCV) may complicate with hepatocellular carcinoma (HCC), especially in patients with cirrhosis. Although the achievement of a sustained virological response (SVR) had been associated with a reduction in the risk of HCC already in the Interferon era, some concerns initially raised following the use of direct-acting antivirals (DAA), as their use was associated with increased risk of HCC development and aggressiveness. However, studies demonstrated that the risk of HCC was strongly influenced by pre-treatment fibrosis stage and, eventually, prior HCC history more than the type of antiviral therapy. According to published studies, rates of de-novo HCC ranged between 1.4% and 13.6% in patients with cirrhosis or advanced fibrosis vs 0.9% and 5.9% in those with chronic hepatitis C (CHC). Conversely, rates of recurrent HCC were higher, ranging between 3.2% and 49% in cirrhotics vs 0% and 40% in CHC patients. Most studies tried to identify predictors of HCC development, either de-novo or recurrent, and some authors were also able to build predictive scores for HCC risk stratification, which however still need prospective validation. Whereas some clinical features, such as age, gender, presence of comorbidities and fibrosis stage, may influence both de-novo and recurrent HCC, previous tumour burden before DAA seems to prevail over these features in recurrent HCC risk prediction.

**Keywords:** hepatocellular carcinoma, HCC, hepatitis C virus, HCV, sustained virological response, SVR, direct-antiviral agent, DAA, surveillance, predictor

## Introduction

Hepatocellular carcinoma (HCC) is currently the fourth cause of liver-related death worldwide,<sup>1,2</sup> and accounts for one of the most frequent indications for liver transplantation. In patients with chronic hepatitis C (CHC), the achievement of a sustained virological response (SVR) to antiviral treatment was demonstrated to reduce the incidence of HCC, already in the Interferon (IFN) era,<sup>3-6</sup> with a more pronounced benefit in those with advanced fibrosis or cirrhosis. After direct-acting antivirals (DAA) approval, a first pivotal study suggested a time-related association between DAA treatment and HCC recurrence,<sup>7</sup> this finding being initially supported by others.<sup>8,9</sup> Similarly, some authors also reported an increased incidence and biological aggressiveness of de-novo HCC arising in cirrhotics successfully treated with DAA.<sup>9-11</sup> Next, evidences eventually raised against a definite role of oral anti-hepatitis C virus (HCV) treatments as HCC promoter.<sup>12-19</sup> Different crude incidences of HCC in IFN vs DAA-treated cirrhotics mostly rely on differences in

Correspondence: Roberta D'Ambrosio  
Division of Gastroenterology and  
Hepatology, Foundation IRCCS Ca' Granda  
Ospedale Maggiore Policlinico, Milan, Italy  
Tel +39-0255035432  
Fax +39-0250320410  
Email roberta.dambrosio@policlinico.mi.it

patient population, as DAA allow treatment of patients with more advanced liver diseases. Following an SVR to DAA-based regimens, reported rates of de-novo HCC are estimated nearly 2–2.5%<sup>17,20–22</sup> vs 20–30% per year<sup>18,19,23</sup> of recurrent HCC, being definitively higher than that historically reported in the setting of IFN.<sup>4</sup> Moreover, HCC risk has been demonstrated to persist up to 10 years from treatment completion.<sup>17</sup>

Taking together, these data still justify the need for long-life surveillance,<sup>1,24</sup> resulting in intensive follow-up of large cohorts of cured HCV patients. Therefore, current literature efforts aim at deeply investigating predictors of HCC in HCV patients cured through SVR, with the ultimate goal of personalized risk stratification and individualized surveillance policies.

Therefore, in this review, we report data from published study analyzing the risk of HCC development, either de-novo or recurrent, following DAA-based treatments. Particularly, we focused on those studies reporting not only full patients' characteristics but also information on HCC rates and predictors.

## Predictors of de-novo HCC

According to published studies, up to 14% of patients without history of previous liver cancer may develop de-novo HCC after HCV eradication, although data vary according to patient population, follow-up duration and severity of liver disease (Table 1).

## Studies Enrolling Patients with Cirrhosis or Advanced Fibrosis

Among 14 studies that reported data in cirrhotic patients,<sup>8,10,20–22,25–37</sup> (Table 2), most were able to identify HCC predictors (Table 3). In addition, 5 studies enrolling patients with CHC and any fibrosis stage also found-out factors associated with de-novo HCC in the subset of patients with cirrhosis<sup>38–42</sup> although unable to provide their clinical features (Tables 4 and 5). Finally, 5 authors reported data on patients with advanced fibrosis, defined through histology (F3-F4), non-invasive tests or criteria for chronic advanced liver disease (cACLD)<sup>11,36,43–46</sup> (Table 2). Eight out of these studies enrolled only patients with an SVR,<sup>10,21,30,33,37,44–46</sup> whilst in one study data could be extrapolated.<sup>34</sup> In studies including also non-SVR patients, rates of treatment failure ranged between 1.9% and 10% (Table 2). Follow-up duration varied according to

**Table 1** Assessment of Liver Fibrosis Severity According to Studies' Designs

Liver Disease Severity	Tool for Staging	Authors
<b>Cirrhosis</b>		
Histology	METAVIR F4	Conti, <sup>8</sup> Cabibbo, <sup>13</sup> Calvaruso, <sup>20</sup> Degasperri, <sup>22</sup> Nahon, <sup>21</sup> Pol, <sup>23</sup> Ravaoli, <sup>25</sup> Degasperri, <sup>26</sup> Rinaldi, <sup>27</sup> Lleo, <sup>28</sup> Degasperri, <sup>31</sup> Finkelmeier, <sup>35</sup> Pinero, <sup>39</sup> Tanaka, <sup>42</sup> Alonso Lopez, <sup>45</sup> Tamaki <sup>48*</sup> , Nagata, <sup>54</sup> Kogiso <sup>65</sup>
Clinical	Any clinical features US features	Cabibbo, <sup>13</sup> Calvaruso, <sup>20</sup> Degasperri, <sup>22</sup> Ravaoli, <sup>25</sup> Rinaldi, <sup>27</sup> Lleo, <sup>28</sup> Degasperri, <sup>26</sup> Degasperri, <sup>31</sup> Sangiovanni, <sup>32</sup> Ogawa, <sup>38</sup> Alonso Lopez, <sup>45</sup> Kwon, <sup>51</sup> Ogawa, <sup>55</sup> Kogiso, <sup>65</sup> Zou <sup>67</sup>
FIB-4	>3.25 Not specified	Tanaka, <sup>42</sup> Nagata, <sup>54</sup> Ide <sup>40</sup>
LSM	≥12 kPa >12 kPa >12.5 kPa ≥12.5 kPa ≥13.5 kPa ≥14.9 kPa >16.2 kPa Not specified	Conti, <sup>8</sup> Bergna, <sup>30</sup> Sangiovanni, <sup>32</sup> Ogasawara <sup>57</sup> Cabibbo, <sup>13</sup> Calvaruso, <sup>20</sup> Casadei-Gardini, <sup>29</sup> Ravaoli, <sup>25</sup> Lleo, <sup>28</sup> Finkelmeier, <sup>35</sup> Virlogeux <sup>61</sup> Pinero, <sup>39</sup> Tanaka, <sup>42</sup> Seholm <sup>53</sup> Rinaldi <sup>27</sup> Ogawa <sup>38</sup> Bergna, <sup>30</sup> Shiha <sup>44</sup> Rinaldi, <sup>36</sup> Ogawa <sup>55</sup>
ICD codes		Kanwal, <sup>34</sup> Kanwal, <sup>41</sup> Zou <sup>67</sup>
<b>Advanced fibrosis</b>		
Histology	METAVIR F3-F4	Nagata <sup>54</sup>
LSM	>9.5 kPa >10 kPa ≥10 kPa >10.2 and ≤16.2 kPa	Pinero, <sup>39</sup> Alonso Lopez <sup>45</sup> Ogawa <sup>38</sup> Pons, <sup>46</sup> Seholm <sup>53</sup> Shiha <sup>44</sup>
FIB-4	>3.25	Tani, <sup>52</sup> Nagata, <sup>54</sup> Watanabe <sup>59</sup>
APRI	≥1	Watanabe <sup>59</sup>

**Notes:** \*Available in 191 out of 346 patients.

**Abbreviations:** F, fibrosis; US, ultrasound; FIB-4, fibrosis-4 index; LSM, liver stiffness measurement; APRI, AST to platelet ratio; ICD, international classification of diseases (code).

study designs as reported in Table 2. Overall, studies reported de-novo HCC rates of 1.8–13.6% in cirrhotics, and of 1.4–4.6% in patients with advanced fibrosis.

**Table 2** Characteristics of Studies Reporting Data on HCC Occurrence (de-novo HCC) in Patients with Cirrhosis or Advanced Fibrosis

Author	Enrollment Period	Study Design	Patients	Males	Age	Fibrosis	CPT Score	SVR	HCC	Follow-Up
<b>Cirrhosis (n=18)</b>										
Conti, 2016 <sup>8</sup>	Italy 2015	Multicenter, retrospective	285	167 (59%)	61 (37–86)	LSM 24.4 ± 0.88	CPT-A 256 CPT-B 29	261 (91.6%)	9 (3.1%) SVR 7 CPT-A 5	24 w <sup>oo</sup>
Cardoso, 2016 <sup>10</sup>	Portugal 2015	Single-center, retrospective	54	38 (70%)	41–81	APRI 1.02–4.04	CPT-A 34	54 (100%)	4 (7.4%) CPT-A 67%	12.0 (IQR 9.4–12.5) m <sup>oooo</sup>
Kanwal, 2017 <sup>34</sup>	US 2015	Multicenter, retrospective	7495 <sup>#</sup>	NA	NA	NA	NA**	7495 (100%)	139 (1.8%)	NA
Ravaoli, 2018 <sup>25</sup>	Italy 2015–2016	Single-center, retrospective	119	91 (65.5%) <sup>§</sup>	63 (52–73) <sup>§</sup>	LSM <sup>§</sup> 18.6 (15.0–26.0) FIB-4 <sup>§</sup> 4.7 (3.0–6.8) APRI <sup>§</sup> 1.67 (0.86–2.63)	CPT-A 108  CPT-B 11	131 (94.2%) <sup>ε</sup>	13 (10.8%)	15 (12–19) m <sup>oo</sup> <sub>ε</sub>
Calvaruso, 2018 <sup>20</sup>	Italy 2015–2016	Multicenter, prospective	2249	1280 (57%)	65 ± 11	LSM 22.4 ± 11.9	CPT-A 2035 CPT-B 214	2140 (95.2%)	78 (3.4%) SVR 64	14 (6–24) m
Nahon, 2018 <sup>21</sup>	France 2014–2016	Multicenter, prospective	336	212 (63%)	59 (54–67)	NA	CPT-A 173 CPT-B 19 CPT-C 1***	336 (100%)	15 (4.5%)	21.2 (IQR 13.5–26.9) m <sup>o</sup>
Finkelmeier, 2018 <sup>35</sup>	Germany 2014–2016	Single-center, retrospective	269	183 (68%)	58 (29–86)	LSM 20.6 (6.1–63.9)	CPT-A 211 CPT-B 50 CPT-C 8	242 (90%)	25 (3.6%) CPT-A 24 CPT-B 1	364 (0–950) d <sup>o</sup>
Degasperi, 2019 <sup>22</sup>	Italy 2014–2016	Single-center, longitudinal	505	302 (60%)	63 (28–87)	LSM 19.1 (12.0–75.0)	CPT-A 442 CPT-B 63	546 (97%) <sup>ε</sup>	28 (4.9%)	25 (3–39) m <sup>o</sup>
Degasperi, 2019 <sup>26</sup>	Italy 2014–2016	Single-center, retrospective	452	58%	63 (28–87)	LSM 19.1 (12.0–75.0) FIB-4 4.9 (0.3–46.0)	CPT-A 393 CPT-B 59	96%	31 (6.9%)	33 (3–47) m <sup>o</sup>

(Continued)

Table 2 (Continued).

Author	Enrollment Period	Study Design	Patients	Males	Age	Fibrosis	CPT Score	SVR	HCC	Follow-Up
Rinaldi, 2019 <sup>27</sup>	Italy 2015–2017	Multicenter, prospective	258	143 (55%)	68 (61–74)	LSM 25.5 (18.0–35.6)	CPT-A 242 CPT-B 16	NA	35 (13.6%) CPT-A 30	NA
Rinaldi, 2019 <sup>36</sup>	Italy 2015–2017	Multicenter, prospective	731	NA	NA	NA	CPT-A 649 CPT-B 82	714 (97.7%)	35 (4.8%) SVR 33 25 CPT-A	48 <sup>oo</sup> w
Lleo, 2019 <sup>28</sup>	Italy 2015	Multicenter, longitudinal	1766	1094 (62%)	1529 (87%) ≥50	500 (28%) LSM ≥25	CPT-A 1561 CPT-B 201	1679 (95.1%)	50 (2.8%) SVR 9 CPT-A 37	NA
Casadei-Gardini, 2019 <sup>29</sup>	Italy 2015–2016	Multicenter, retrospective	416	242 (58%)	63 (31–90)	NA	CPT-A 351 CPT-B 65	NA	29 (7%)	18 (0.4–26.4) m <sup>c</sup>
Abe, 2020 <sup>37</sup>	Japan	Multicenter, retrospective	188	90 (48%)	70 (61–77)	FIB-4 6.2 (4.3–8.7)	CPT-A 188*	188 (100%)	19 (10%)	46 (37–52) m <sup>oo</sup>
Degasperi, 2020 <sup>31</sup>	Italy 2014–2016	Single-center, retrospective	452	261 (58%)	63 (28–87)	LSM 17.4 (12.0–75.0) FIB-4 4.9 (0.3–46.3)	CPT-A 393 CPT-B 59	96% <sup>c</sup>	36 (7.9%) CPT-A 31	43 (3–57) m
Sangiovanni, 2020 <sup>32</sup>	Italy 2015–2017	Multicenter, prospective	1161	686 (59%)	65 (22–85)	NA	CPT-A 1066	1119 (96%)	48 (4.1%) SVR 47	17 (3–43) m
Fan, 2020 <sup>33</sup>	East Asia, Europe, US 2014–2016	Prospective, observational cohorts or RCT	2489	71%	55 (46–63%)	NA	2,489 (100%)* <sup>**</sup>	2489 (100%)	NA	NA
Bergna, 2021 <sup>30</sup>	Italy	Single-center, retrospective	577	58%	64	LSM 17.3	CPT-A 513 CPT-B 64	577 (100%)	46 (8%)	52 (8–62) m
<b>Advanced Fibrosis (n=5)</b>										
Romano, 2018 <sup>11</sup>	Italy 2015–2017	Multicenter, prospective	3917 F3/ F4	2437 (62%)	58 (21–90)	LSM 18.8 (1.1–75.0) FIB-4 4.7 (3.0–6.8) APRI 1.8 (0.1–43.1)	2958* <sup>***</sup> (CPT-A 2388) (CPT-B 352)	2637 (94%)	55 (1.4%) SVR 33 F4 55 CPT-A 38	536 ± 198 d

Rinaldi, 2019 <sup>36</sup>	Italy 2015–2017	Multicenter, prospective	985 F3/ F4	543 (55%)	67 (59–73)	LSM 17.3 (11.9–35.3)	731 (CPT-A 649) (CPT-B 82)	966 (98.1%)	35 (3.6%) SVR 33 F4 35 CPT-A 25	48 w <sup>oo</sup>
Shiha, 2020 <sup>44</sup>	Egypt 2015–2018	Multicenter, observational	2372 F3/ F4	1242 (52%)	56 (50–62)	NA	1734 (CPT-A 1294) (CPT-B 440)	2372 (100%)	109 (4.6%) F4 101 CPT-A 66	23.6 ± 8.3 m <sup>oo</sup>
Alonso Lopez, 2020 <sup>45</sup>	Spain 2015–2017	Multicenter, observational	993 F3/ F4	551 (55.5%)	62 (26–88)	LSM 19.0 ± 10.7 FIB-4 4.1 ± 3.8	NA*	993 (100%)	35 (3.9%)	17 (3–43) m <sup>o</sup>
Pons, 2020 <sup>46</sup>	Spain 2015–2016	Multicenter, prospective	572 cACLD	282 (49.3%)	64 ± 11	LSM 20.2 ± 10.4 FIB-4 5.6 ± 4.4	NA*	572 (100%)	25 (4.4%)	2.9 (0.3–3.8) y

**Notes:** Values are expressed as median (range), mean ± standard deviation and/or percentages (%). Age is calculated in years-old; LSM is calculated in kPa. <sup>oo</sup>From DAA start; <sup>o</sup>From EOT; <sup>oo</sup>From SVR12; <sup>oo</sup>From SVR24; <sup>oo</sup>From HCV-RNA undetectability. <sup>#</sup>Patients with and without an SVR were included in the study. <sup>o</sup>Available for patients with and without HCC history. <sup>\*\*</sup>Only CPT-A patients included; <sup>\*\*\*</sup>CPT criteria at enrollment not available; <sup>\*\*\*\*</sup>CPT score available in 193; <sup>\*\*\*\*\*</sup>CPT score available in 2640. LSM by FibroScan<sup>®</sup>.

**Abbreviations:** HCC, hepatocellular carcinoma; CPT, Child-Pugh-Turcotte score; SVR, sustained virological response; F, fibrosis; LSM, liver stiffness measurement; IQR, interquartile range; w, weeks; NA, not available; FIB-4, fibrosis-4 index; APRI, AST to platelet ratio index; m, months; y, years; F4, cirrhosis; US, United States; cACLD, chronic advanced liver disease; DAA, direct-acting antivirals; EOT, end of treatment; RCT, randomized controlled trials.

**Table 3** Incidence and Risk Factors of de-novo HCC in Patients with Cirrhosis or Advanced Fibrosis

Author	SVR Status	Incidence of HCC (CumI)								Independent Predictors	
		100 PY									
		6-Month	1-Year	1.5-Year	2-Year	3-Year	4-Year	5-Year			
<b>Cirrhosis (n=16)</b>											
Conti, 2016 <sup>8</sup>	SVR + non-SVR	3.1%	-	-	-	-	-	-	-	-	NA
Cardoso, 2016 <sup>10</sup>	SVR	-	-	-	-	-	-	-	-	-	None
Kanwal, 2017 <sup>34</sup>	SVR	-	-	-	-	-	-	-	-	1.82	Race (Hispanic)
Ravaoli, 2018 <sup>25</sup>	SVR + non-SVR	-	-	-	-	-	-	-	-	-	ΔLSM <30%, CPT-B
Calvaruso, 2018 <sup>20</sup>	SVR + non-SVR <sup>c</sup>	-	SVR 2.9% CPT-A SVR 2.1% CPT-B SVR 7.8%	-	-	-	-	-	-	-	Albumin, PLT, non-SVR
Nahon, 2018 <sup>21</sup>	SVR + non-SVR	-	-	-	-	5.9%	-	-	-	SVR 1.4 Non-SVR 14	Age >50 years, past alcohol, HCV-1, PLT <150/mm <sup>3</sup> , γGT ≥2 ULN
Finkelmeier, 2018 <sup>35</sup>	SVR + non-SVR	-	-	-	-	-	-	-	-	-	Non-SVR
Degasperi, 2019 <sup>22</sup>	SVR + non-SVR	1.4%	3.4%	4.7%	5.7%	6.0%	-	-	-	-	<b>Model 1:</b> Male gender, LSM, DM <b>Model 2:</b> Male gender, FIB-4, DM
Degasperi, 2019 <sup>26</sup>	SVR + non-SVR	-	-	-	-	7.5%	-	-	-	-	Male gender, FIB-4, DM
Rinaldi, 2019 <sup>27</sup>	SVR + non-SVR	-	-	-	-	-	-	-	-	-	Age, LSM, PLT
Rinaldi, 2019 <sup>36</sup>	SVR + non-SVR	-	4.7%	-	-	-	-	-	-	-	Male gender, DM, SOF-based + RBV-free therapy, CPT-B
Lleo, 2019 <sup>28</sup>	SVR + non-SVR	0.9%	2.4%	3.5%	-	-	-	-	-	-	Age (≥50 years), non-SVR, EV

Casadei-Gardini, 2019 <sup>29</sup>	NA	0.010 <sup>oo</sup>	0.05 <sup>oo</sup>	0.072 <sup>oo</sup>	-	-	-	-	-	-	ALBI, PLT
Abe, 2020 <sup>37</sup>	SVR	-	2.6%	-	4.9%	9.3%	11.5%	-	-	-	<b>Model 1:</b> ALBI (2,3) <b>Model 2:</b> ALBI (2,3), DM, PLT
Degasperi, 2020 <sup>31</sup>	SVR + non-SVR	-	-	-	-	-	9%	-	-	-	Male gender, albumin, DM, GRS >0.597
Sangiovanni, 2020 <sup>32</sup>	SVR + non-SVR	-	-	-	-	7.8%	-	-	-	3.1	αFP, ascites, UNMIN
<b>Advanced fibrosis (n=5)</b>											
Romano, 2018 <sup>11</sup>	SVR + non-SVR	-	F3 0.46% F4 1.18% CPT-A 1.49% CPT-B 3.61%	-	F3 0% F4 NA CPT-A 0.20% CPT-B 0.69%	-	-	-	-	0.97	<b>F4:</b> APRI >2.5, HBV co-infection
Rinaldi, 2019 <sup>36</sup>	SVR + non-SVR	-	3.6%	-	-	-	-	-	-	-	Male gender, LSM, DM, SOF-based + RBV-free therapy
Shiha, 2020 <sup>44</sup>	SVR	-	-	-	-	-	-	-	-	2.3	Age, male gender; αFP, albumin, cirrhosis
Alonso Lopez, 2020 <sup>45</sup>	SVR	-	1.4%	-	2.2%	4.1%	-	-	-	-	LSM, albumin, ΔLSM (1-year), ΔFIB-4 (1-year)
Pons, 2020 <sup>46</sup>	SVR	-	-	-	-	-	-	-	-	1.5	<b>Pre-DAA:</b> albumin <b>SVR48:</b> albumin + LSM <10 kPa

**Notes:** <sup>oo</sup> Cuml are available for SVR patients, only (vs predictors of HCC); <sup>oo</sup> cumulative Hazards of HCC occurrence. LSM by FibroScan<sup>®</sup>.  
**Abbreviations:** HCC, hepatocellular carcinoma; SVR, sustained virological response; Cuml, cumulative incidence; PY, person/year; F4, cirrhosis; NA, not available; LSM, liver stiffness measurement; CPT, Child-Pugh-Turcotte score; PLT, platelets; HCV, hepatitis C virus; γGT, γ-glutamyl-transferase; DM, diabetes mellitus; FIB-4, Fibrosis-4 index; SOF, sofosbuvir; RBV, ribavirin; EV, esophageal varices; CSPH, clinically significant portal hypertension; ALBI, albumin-bilirubin score; MELD, model for end-stage liver disease; αFP, alpha-fetoprotein; GRS, genetic risk score; UNMIN, undefined/non-malignant nodule; HBV, hepatitis B virus; DAA, direct-acting antivirals.

**Table 4** Characteristics of Studies Reporting Data on HCC Occurrence (de-novo HCC) in Patients with Chronic Hepatitis C (Any Fibrosis Stage)

Author	Enrollment Period	Study Design	Patients	Males	Age	Fibrosis	Cirrhosis (F4)	SVR	HCC (Number)	Follow-Up
<b>Any Fibrosis Stage (n=23)</b>										
Kanwal, 2017 <sup>34</sup>	US 2015	Multicenter, retrospective	19,518 <sup>#</sup>	18,851 (97%)	62 ± 6	NA	7495 (38%)**	19,518 (100%)	183 (0.9%)	20,415 PY
Tachi, 2017 <sup>56</sup>	Japan 2014–2015	Multicenter, prospective	233	108 (46%)	16–88	ARFI 0.67–4.35	NA**	233 (100%)	7 (3.0%)	18.1 (5.6–31.2) m <sup>°</sup>
Nagata, 2017 <sup>54</sup>	Japan 2014–2017	Multicenter, retrospective	669	340 (45%) <sup>‡</sup>	69 (24–87) <sup>‡</sup>	FIB-4 3.0 (0.2–74.7) <sup>‡</sup>	F3-F4** 108 (33%) <sup>‡</sup>	722 (96%) <sup>‡</sup>	7 (1.1%)	1.8 (0.1–7.7) y <sup>‡</sup>
Ogawa, 2018 <sup>38</sup>	Japan 2015–2016	Multicenter	1523	660 (43%)	66 (54–73)	NA	271 (18%)*	1523 (100%)	20 (1.3%)	17 (1–23) m <sup>°</sup>
Finkelmeier, 2018 <sup>35</sup>	Germany 2014–2016	Single-center, retrospective	819	470 (57%)	55 (18–86)	LSM 5.6 ± 9.4	269 (33%) (CPT-A 211) (CPT-B 50) (CPT-C 8)	764 (93.3%)	25 (3%) SVR 20 F4 25 CPT-A 24	263 (0–1001) d <sup>°</sup>
Degasperi, 2019 <sup>36</sup>	Italy 2014–2016	Single-center, retrospective	348	48%	60 (21–88)	LSM 8.1 (2.0–11.9)	0	NA	3 (0.9%)	23 (5–42)
Rinaldi, 2019 <sup>36</sup>	Italy 2015–2017	Multicenter, prospective	966	529 (55%)	67 (59–73)	LSM 16.0 (22.8–23.0)	731 (76%)	966 (100%)	35 (3.6%)	48 w <sup>°</sup>
Watanabe, 2019 <sup>50</sup>	Japan 2014–2017	Multicenter, retrospective	1174 <sup>#</sup>	540 (46%)	65.3 (23–88)	NA	NA**	1174 (100%)	33 (2.8%)	539 d <sup>°</sup>
Hiraoka, 2019 <sup>60</sup>	Japan 2014–2017	Multicenter, retrospective	1069 (484 DC, 585 VC)	478 (48%)	67 ± 11	FIB-4 2.76±1.77	NA**	1069 (100%)	36 (3.4%) 14 DC, 22 VC	16.3 ± 9.5 m <sup>°</sup>
Tamaki, 2019 <sup>48</sup>	Japan 2015–2017	Single-center	346	126 (36%)	68 ± 10	NA	21 (6%)*	346 (100%)	24 (6.9%)	26.4 ± 7.9 m <sup>°</sup>
Higuchi, 2019 <sup>48</sup>	Japan 2015–2017	Single-center	304	109 (36%)	68 ± 11	I45 (48%) FIB-4 >3.245	NA**	304 (100%)	18 (5.9%)	21.1 ± 6.5 m <sup>°</sup>
Ito, 2019 <sup>47</sup>	Japan 2014–2018	Multicenter, retrospective	1029	435 (42%)	NA (20–90)	NA	NA*	1029 (100%)	19 (1.8%)	104 w <sup>°</sup>
Pinero, 2019 <sup>39</sup>	S. America 2016–2018	Multicenter, prospective	1400	668 (48%)	58 ± 12	NA	784 (56%)* CSPH 399	1114/1149 (96.9%)	30 (2.3%) F4 28	16 (IQR 8.9–23.4) m <sup>°</sup>
Ide, 2019 <sup>40</sup>	Japan 2015–2017	Multicenter, prospective	2552	1003 (40%)	65 (20–92)	FIB-4 3.86 ± 3.22	648 (25%)*	2552 (100%)	70 (2.7%) F4 35	22.6 ± 8.3 m <sup>°</sup>



Kwon, 2019 <sup>51</sup>	Korea 2015–2017	Multicenter retrospective	562	264 (45%) <sup>‡</sup>	59 ± 12 <sup>‡</sup>	NA	172 (29%) <sup>***‡</sup>	461/487 (97%) <sup>‡</sup>	15 (2.6%) SVR 15 F4 I0	1 y <sup>***‡</sup>
Ogasawara, 2020 <sup>57</sup>	Japan 2010–2017	Single-center retrospective	398	154 (38%)	70 (25–88)	LSM 8.6 (2.4–49.6) FIB-4 3.00 (0.63–19.15)	NA*	398 (100%)*	19 (4.8%)	3.3 (0.5–7.1) y <sup>***</sup>
Tani, 2020 <sup>52</sup>	Japan 2014–2018	Multicenter	1088	545 (50%)	68 (58–75)	FIB-4 2.94 (1.85–4.63) APRI (0.86–1.55)	191 (18%) <sup>**</sup>	1088 (100%)	26 (2.4%) F4 I0	13.8 m <sup>oo</sup>
Kanwal, 2020 <sup>41</sup>	US 2015	Multicenter retrospective	18,076	17,446 (96.5%)	62 ± 6	56.14 (28.8%)	6938 (38.4%) <sup>**</sup>	18,076 (100%)	544 (3.0%)	2.93 ± 0.56 y <sup>oo</sup>
Abe, 2020 <sup>37</sup>	Japan	Multicenter retrospective	880 (F0-F3)	421 (48%)	66 (56–74)	FIB-4 2.4 (1.6–3.6)	0	880 (100%)	20 (2.2%)	42 (31–48) m <sup>oo</sup>
Tanaka, 2020 <sup>42</sup>	East Asia 2014–2018	Multicenter retrospective	5646 <sup>#</sup>	2404 (43%)	64 ± 12	3.81 ± 3.24	2911 (52%) (CPT-A 1314) (CPT-B/C 79)	5646 (100%)	244 (4.3%) F4 221	2.93 y <sup>***</sup>
Ogawa, 2020 <sup>55</sup>	Japan 2014–2019	Multicenter retrospective	2405	1057 (43.9%)	43–81	1.02–5.74	501 (21%) <sup>*</sup>	2405 (100%)	64 (2.7%)	3.5 (1–5.2) y <sup>o</sup>
Watanabe, 2020 <sup>59</sup>	Japan 2014–2017	Multicenter retrospective	1438	663 (46%)	66 ± 10	NA	NA <sup>**</sup>	1401 (97%)	55 (3.8%)	803 days <sup>oo</sup>
Seholm, 2020 <sup>53</sup>	Denmark 2012–2019	Multicenter retrospective	773 CHC	492 (64%)	54 (45–61)	LSM 11.6 (2.5–75.0)	F3-F4 45 (58%)	773 (100%)	11 (1.4%) F3-F4 I0	36 (6–82) m <sup>*****</sup>

**Notes:** Values are expressed as median (range), mean ± standard deviation and/or percentages (%). Age is calculated in years-old; LSM is calculated in kPa. <sup>‡</sup>From DAA start; <sup>\*\*\*</sup>From SVR24; <sup>oo</sup>From pLSM. <sup>#</sup>Patients with and without an SVR were included in the study. <sup>o</sup>Available for patients with and without HCC history. <sup>\*</sup>Only CPT-A patients included; <sup>\*\*</sup>CPT criteria at enrollment not available. LSM by FibroScan<sup>®</sup>. **Abbreviations:** HCC, hepatocellular carcinoma; SVR, sustained virological response; US, United States; PY, person-years; F4, cirrhosis; F, fibrosis; LSM, liver stiffness measurement; ARFI, acoustic radiation force impulse; DC, derivation cohort; VD, validation cohort; CPT, Child-Pugh-Turcotte score; w, weeks; m, months; y, years; NA, not available; FIB-4, fibrosis-4 index; APRI, AST to platelet ratio index; CSPH, clinically significant portal hypertension; IQR, interquartile range; DAA, direct-acting antivirals; EOT, end of treatment; pLSM, pre-treatment LSM.

**Table 5** Incidence of de-novo HCC and Factors Associated with HCC Occurrence (de-novo HCC) in Patients with Chronic Hepatitis C (Any Fibrosis Stage) from 21 Studies

Author	SVR Status	Incidence of HCC (Cuml)										Independent Predictors
		Cuml										
		6-Month	1-Year	1.5-Year	2-Year	3-Year	4-Year	5-Year	100 PY			
Kanwal, 2017 <sup>34</sup>	SVR	-	-	-	-	-	-	-	-	-	0.90	<b>F0-F3:</b> FIB-4 ≥3.25, DM, alcohol <b>Overall:</b> cirrhosis, alcohol, race
Tachi, 2017 <sup>56</sup>	SVR	-	2.3%	-	4.3%	-	-	-	-	-	-	LSM by ARFI
Nagata, 2017 <sup>54</sup>	SVR + non-SVR	-	-	-	-	1.4%	-	-	-	-	-	IL28B, SVR24 WFA*M2BP
Ogawa, 2018 <sup>38</sup>	SVR	-	<b>F0-F3</b> 0.4% <b>F4</b> 4.9%	-	-	-	-	-	-	-	-	<b>Overall:</b> EOT-αFP, cirrhosis <b>F0-F3:</b> PLT, advanced fibrosis <b>F4:</b> EOT-αFP, portal hypertension
Degasperi, 2019 <sup>26</sup>	SVR + non-SVR	-	-	-	-	2%	-	-	-	-	-	<b>NA</b>
Watanabe, 2019 <sup>30</sup>	SVR	-	1.9%	3.2%	4.1%	-	-	-	-	-	-	<b>Pre-DAA:</b> male gender, albumin, FIB-4 <b>EOT:</b> FIB-4, αFP
Hiraoka, 2019 <sup>60</sup>	SVR	-	-	-	-	-	-	-	-	-	-	Male gender, SVR12-FIB-4 >3.25, SVR12-αFP >5 ng/mL
Tamaki, 2019 <sup>48</sup>	SVR	-	-	-	-	-	-	-	-	-	-	Age, SVR12-αFP ≥6.5 ng/mL, SVR12-LSM by MRE ≥3.75 kPa, LR3/4 nodules
Higuchi, 2019 <sup>58</sup>	SVR	-	-	-	-	-	-	-	-	-	-	Age, SVR12-LSM by MRE ≥3.75, SVR-12 αFP ≥6 ng/mL
Iio, 2019 <sup>47</sup>	SVR	-	-	-	-	-	-	-	-	-	-	αFP >4.6 ng/mL, FIB-4 >2.67, TLLI AT/TT
Pinero, 2019 <sup>39</sup>	SVR + non-SVR	-	<b>Overall</b> 0.02% <b>F4</b> 0.003%	-	<b>Overall</b> 0.04% <b>F4</b> 0.06%	-	-	-	-	-	-	<b>Overall:</b> CSPH, non-SVR, previous IFN <b>F4:</b> CSPH, non-SVR

Ide, 2019 <sup>40</sup>	-	Overall 1.3% F0-F3 0.9% F4 2.5%	-	Overall 2.9% F0-F3 2.1% F4 5.2%	Overall 4.9% F0-F3 2.9% F4 10.0%	-	-	-	Overall: Male gender, age>62, FIB-4, $\gamma$ GT F0-F3: Male gender, age, $\gamma$ GT F4: Male gender, FIB-4 $\geq$ 4.6
Kwon, 2019 <sup>61</sup>	-	-	-	-	-	-	-	-	EOT- $\alpha$ FP
Ogasawara, 2020 <sup>57</sup>	-	0.8%	-	3.0%	-	6.0%	-	-	LSM $\geq$ 20 kPa, $\alpha$ FP $\geq$ 8 ng/mL, SVR24-LSM $\geq$ 10 kPa
Tani, 2020 <sup>52</sup>	0.61%	1.88%	2.82%	3.71%	6%	-	-	-	Age>75, post-EOT $\alpha$ FP
Kanwal, 2020 <sup>41</sup>	-	Overall 1.1% F4 2.2%	-	Overall 1.9% F4 5.6% F4 3.8%	Overall 2.8% F4: Age, race (non-African American, MELD)	-	-	-	Overall: Age, race (non-African American), alcohol, HCV-3
Abe, 2020 <sup>37</sup>	-	0.7%	-	1.1%	1.8%	3.0%	-	-	F0-F3: albumin
Tanaka, 2020 <sup>42</sup>	-	-	-	-	-	-	F0-F3 1.35% F4 14.9%	-	F0-F3: $\alpha$ FP $\geq$ 10 ng/mL F4: Age $\geq$ 60, $\alpha$ FP $\geq$ 10 ng/m, ALBI 2-3
Ogawa, 2020 <sup>55</sup>	-	-	-	-	-	-	-	0.56- 3.61	Pre-DAA: Age (60-84), male gender, cirrhosis SVRI2: albumin, ALT, $\alpha$ FP, $\Delta$ FIB-4
Watanabe, 2020 <sup>59</sup>	-	Overall 2.3% Females 1.3% Males 3.2%	-	Overall 3.9% Females 2.8% Males 5.2%	Overall 4.9% Females 3.4% Males 6.7%	Overall 14.4% Females 8.8% Males 19.2%	-	-	Females: FIB-4, EOT- $\alpha$ FP Males: EOT- $\alpha$ FP
Seholm, 2020 <sup>53</sup>	-	-	-	-	-	-	-	0.5	Age, LSM $\geq$ 17.5 kPa

Notes: Values are expressed as median (range), mean  $\pm$  standard deviation and/or percentages (%), LSM by FibroScan<sup>®</sup>.

Abbreviations: HCC, hepatocellular carcinoma; SVR, sustained virological response; CumI, cumulative incidence; PY, person/year; F, fibrosis; F4, cirrhosis; FIB-4, fibrosis-4 index; DM, diabetes mellitus; LSM, liver stiffness measurement; ARFI, acoustic radiation force impulse; DAA, direct-acting antivirals; WFA<sup>®</sup>M2BP, *Wisteria floribunda* agglutinin positive Mac-2 binding protein; EOT, end of treatment;  $\alpha$ FP, alpha-fetoprotein; MRE, magnetic resonance elastography; TLL1, tolloid-like 1 gene; IFN, interferon; CSPH, clinically significant portal hypertension;  $\gamma$ GT,  $\gamma$ -glutamyl-transferase; HCV, hepatitis C virus; ALT, alanine aminotransferase.

**Table 6** Cumulative Incidence (CumI) of HCC According to Values of Clinically Significant Variables

Author	Fibrosis	Clinical Variables	Cut-Off	1-Year	2-Year	3-Year	4-Year
<b>de-novo HCC</b>							
Ogawa, 2018 <sup>38</sup>	F4	EOT- $\alpha$ FP	<9 vs $\geq$ 9 ng/mL	1.4% vs 13.1%	-	-	-
Degasperi, 2019 <sup>22</sup>	F4	LSM by TE (Model 1)	$\leq$ 30 vs >30 kPa	-	-	5% vs 20%	-
		FIB-4 (Model 2)	$\leq$ 9 vs >9	-	-	5% vs 10%	-
Rinaldi, 2019 <sup>27</sup>	F4	LSM by TE*	<20 vs 20–30 vs >30 kPa	-	-	-	-
Abe, 2020 <sup>37</sup>	F4	ALBI	$\leq$ 2.3 vs >2.3	1.6% vs 7.5%	2.4% vs 11.5%	4.2 vs 23.4%	5.2 vs 26.3%
	F4	PLT**	$\geq$ 82 vs <82 $10^3$ /mm <sup>3</sup>	-	-	-	-
	F4	DM**	No vs Yes	-	-	-	-
Degasperi, 2020 <sup>31</sup>	F4	Gender	Female vs Male	-	-	-	6% vs 12%
	F4	DM	No vs Yes	-	-	-	7% vs 17%
	F4	Albumin	$\geq$ 3.5 vs <3.5	-	-	-	7% vs 21%
	F4	GRS	$\leq$ 0.597 vs >0.597	-	-	-	7% vs 16%
Pons, 2020 <sup>46</sup>	cACLD	SVR48-LSM ***	<10 vs. 10–20 vs $\geq$ 20 kPa	-	-	-	-
	cACLD	Albumin***	<4 vs $\geq$ 4 g/dl	-	-	-	-
Tachi, 2017 <sup>56</sup>	CHC	LSM by ARFI	<1.73 vs $\geq$ 1.73	1.2 vs 6.1%	1.2 vs 13.4%	-	-
Tamaki, 2019 <sup>48</sup>	CHC	SVR12-LSM by MRE	<3.75 vs $\geq$ 3.75 kPa	1.4% vs 6.6%	2.5% vs 11.9%	2.5% vs 14.5%	-
Iguchi, 2019 <sup>58</sup>	CHC	SVR12-LSM by MRE	<3.75 vs $\geq$ 3.75 kPa	0.5% vs 6.7%	1.7% vs 11.9%	-	-
Watanabe, 2019 <sup>50</sup>	CHC	FIB-4 < vs $\geq$ 4****	<4 vs $\geq$ 4	-	-	-	-
	CHC	Albumin*****	<3.8 vs $\geq$ 3.8 g/dl	-	-	-	-
	CHC	Gender*****	Female vs Male	-	-	-	-
	CHC	$\alpha$ FP*****	<6 vs $\geq$ 6 ng/mL	-	-	-	-
Iio, 2019 <sup>47</sup>	CHC	TLLI	AA vs AT/TT	1.3% vs 3.6%	1.5% vs 5.5%	-	-
Seholm, 2020 <sup>53</sup>	CHC	LSM by TE*****	<17.5 vs $\geq$ 17.5 kPa	-	-	-	-
Watanabe, 2020 <sup>59</sup>	CHC	Gender	Female vs Male	1.3% vs 3.2%	2.8% vs 5.2%	3.4% vs 6.7%	8.8% vs 19.2%
	CHC	$\alpha$ FP (females)*****	<6 vs $\geq$ 6 ng/mL	-	-	-	-
	CHC	$\alpha$ FP (males)*****	<3.5 vs $\geq$ 3.5 ng/mL	-	-	-	-
Abe, 2020 <sup>37</sup>	F0-F3	Albumin*****	$\geq$ 3.95 vs <3.95 g/dl	-	-	-	-
	F0-F3	$\alpha$ FP*****	<6 vs $\geq$ 6 ng/mL	-	-	-	-



**Table 7** Studies Reporting Predictive Scores for de-novo HCC

Study	Fibrosis	Score Name	Variables Included	Algorithm	Risk Classes	HCC Rate According to Risk Classes
Abe, 2020 <sup>37</sup>	F4	NA	ALBI score <sup>o</sup> PLT <sup>o</sup> DM status	0 or 1 points ALBI score ≤ or >2-3 PLT ≥ or < 8.2 x 10 <sup>4</sup> /μL Absence or presence of DM	0-1 Low-score 2-3 High-score	Low vs High-score Group 0.7% vs 12.5% at 1 yr 2.2% vs 15.2% at 2 yrs 3.1% vs 33.9% at 3 yrs 3.1% vs 41.2% at 4 yrs
Fan, 2020 <sup>33</sup>	F4	aMAP	Age Gender Bilirubin Albumin PLT	Mathematical Formula	<50 Low-risk 50-60 Intermediate Risk >60 High-Risk	Low vs Intermediate vs High-Risk 0-0.8% vs 1.5-4.8% vs 8.1-17.8% at 3-5 yrs
Shiha, 2020 <sup>44</sup>	F3-F4 <sup>#</sup>	GES	Age <sup>o</sup> Male gender αFP <sup>o</sup> Albumin <sup>o</sup> Fibrosis	0 points to 3.5 points Female vs Male Age ≤ or > 54 years Albumin ≥ or <3.8 g/dl αFP ≤ or >20 ng/mL F3 or F4	GES ≤6 Low Risk GES 6-7.5 Intermediate Risk GES >7.5 High Risk	Low vs Intermediate vs High-Risk 0.1% vs 0.7% vs 1.2% at 1 yr 1.2% vs 3.3% vs 7.1% at 2 yrs 1.9% vs 5.8% vs 9.5% at 3 yrs
Alonso-Lopez, 2020 <sup>45</sup>	F3-F4 <sup>*</sup>	NA	LSM Model Albumin <sup>o</sup> LSM <sup>o</sup> SVR48 ΔLSM <sup>§</sup> FIB-4 Model Albumin <sup>o</sup> FIB-4 <sup>o</sup> SVR48 FIB-4 <sup>§</sup> SVR48 γGT <sup>§</sup>	LSM Model (0 or 1 points) Albumin ≥ or < 4.2 g/dl LSM ≤ or > 17.3 kPa ΔLSM ≥ or <25.5% FIB-4 Model (0 to 2 points) Albumin ≥ or <4.2 g/dl FIB-4 ≤ or >3.7 SVR48 FIB-4 ≤ or >3.3 SVR48 γGT ≤ or >42 U/l	LSM Model Score 0-1-2-3 FIB-4 Model Score 1-2 vs 3-4 vs 5-6	LSM Model Score 0 vs 1 vs 2 vs 3 0% vs 2.1% vs 5.8% vs 16.3% at 3 yrs FIB-4 Model Score 1-2 vs 3-4 vs 5-6 0.4% vs 1.7% vs 6.5 vs 19% at 3 yrs

Watanabe, 2019 <sup>50</sup>	CHC	NA	<p><b>Pre-DAA Model</b> FIB-4<sup>§</sup> Albumin<sup>°</sup> Gender</p> <p><b>Post-DAA Model</b> EOT FIB-4 EOT AFP</p>	<p><b>Pre-DAA Model</b> 0 or 1 points FIB-4 &lt; or ≥4.0 Albumin &gt; or ≤3.8 g/dl Female or Male</p> <p><b>Post-DAA Model</b> 0 or 1 points FIB-4 &lt; or ≥4.0 AFP &lt; or ≥6.0 ng/mL</p>	<p><b>Pre-DAA Model</b> 0 Low Risk 1-2 Intermediate Risk 3 High Risk</p> <p><b>Post-DAA Model</b> 0 Low 1 Intermediate 2 High</p>	<p><b>Pre-DAA Model</b> Low vs Intermediate vs High Risk 0.4% vs 2.1% vs 9.5% at 1 yr 0.4% vs 4.4% vs 16.4% at 2 yrs</p> <p><b>Post-DAA Model</b> Low vs Intermediate vs High Risk 0.4% vs 1.4% vs 6.1% at 1 yr 0.4% vs 3.2% vs 14.4% at 2 yrs</p>
Hiraoka, 2019 <sup>60</sup>	CHC	ADRES	<p>Gender SVR24 FIB-4 SVR24 αFP</p>	<p>1 point to each variable Male FIB-4 &gt;3.25 αFP &gt;5 ng/mL</p>	<p>ADRES 0-1-2-3</p>	<p>ADRES 0 vs 1 vs 2 vs 3 0% vs 0.5% vs 8.4% vs 18% at 1 yr 0% vs 1.6% vs 13.4% vs 32.8% at 2 yrs</p>
Ito, 2019 <sup>47</sup>	CHC	NA	<p>SVR24 AFP SVR24 FIB-4 TLLI AA/TT</p>	<p>1 point to each variable αFP &gt;4.6 ng/mL FIB-4 &gt;2.67 TLLI AA/TT</p>	<p>0 Low Risk 1-2 Intermediate Risk 3 High Risk</p>	<p>Low vs Intermediate vs High Risk 0% vs 2.2% vs 10.4% at 1 yr 0% vs 3.0% vs 13.6% at 2 yrs</p>
Tani, 2020 <sup>52</sup>	CHC	NA	<p>EOT Age EOT αFP</p>	<p>0 to 1 points Age &lt; or ≥75 years-old AFP &lt; or ≥6 ng/mL</p>	<p>Score 0-1-2</p>	<p>Score 0 vs 1 vs 2 0.3% vs 1.05% vs 4.92% at 1 yr 0.3% vs 6.27% vs 18.37% at 2 yrs 1.26% vs 10.45% vs 18.37% at 3 yrs</p>

Notes: <sup>§</sup> Pre-DAA; <sup>°</sup> 1 year after EOT; \* LSM > 9.5 kPa; <sup>†</sup> LSM > 10.2 kPa; <sup>‡</sup> LSM > 10.2 kPa for F3; LSM > 16.3 for F4.

Abbreviations: ALBI, Albumin to Bilirubin Index; αFP, Alpha-fetoprotein; CHC, Chronic Hepatitis C; DAA, Direct-acting antivirals; DM, Diabetes; EOT, End of Treatment; FIB-4, Fibrosis-4 index; γGT, gamma-glutamyl transferase; HCC, Hepatocellular carcinoma; LSM, Liver Stiffness Measurement; PLT, platelets; SVR, Sustained Virological Response; TLLI, Tolloid-like protein 1; yr, year; yrs, years; 24SVR, 24 weeks after EOT; SVR48, 48 weeks after EOT.

baseline FIB-4 >3.7 and FIB-4 >3.3 one year after treatment were associated with de-novo HCC<sup>45</sup> (Table 7). Other NITs had been investigated as predictors of HCC in several studies: the albumin-bilirubin (ALBI) score grade 2–3<sup>29,37,42</sup> and AST to platelet (PLT) ratio index (APRI) >2.5<sup>11</sup> emerged as independent risk factors for de-novo HCC in patients with cirrhosis and advanced fibrosis, respectively.

#### Portal Hypertension and Surrogates of Advanced Liver Disease

The risk of de-novo HCC was also increased in cirrhotic patients with clinical features of more advanced liver disease, irrespective of LSM and/or NIT values. The presence of portal hypertension (PH) was an independent predictor of HCC in several studies, although definition of PH was heterogeneous. Ogawa et al defined PH by either LSM values ( $\geq 20$  kPa) or hepatic venous pressure gradient (HVPG; >10 mmHg), or by imaging.<sup>38</sup> Thus, among indirect markers of PH were both biochemical tests and clinical features. For example, albumin<sup>20,31,37,44,45</sup> and PLT<sup>20,21,27,29</sup> were independently associated with HCC occurrence, either as single predictors or when included in predictive scores (Tables 6 and 7). The presence of esophageal varices (EV)<sup>28</sup> or ascites was associated with an increased the risk of de-novo HCC.<sup>32</sup>

Clinical scores incorporating these parameters, such as Child-Pugh-Turcotte (CPT)<sup>25,36</sup> and Model for End Stage Liver Disease (MELD)<sup>41</sup> or ALBI scores<sup>29,37,42</sup> were independently associated with de-novo HCC in cirrhotics (Table 7). Some studies provided different CumI of de-novo HCC according to the combination of one or more variables associated with portal hypertension (see below).

#### Patient-Related Factors

Several patients' features, either modifiable or not modifiable, have been shown to increase the risk of de-novo HCC after the achievement of an SVR. Age was independently associated with HCC occurrence in most studies<sup>21,27,28,40–42,44</sup> as well as male gender<sup>22,26,31,36,40,44</sup> (Tables 3 and 5). In US cohorts, a role of non-African American ethnicity has been suggested,<sup>34,41</sup> although this association deserves further confirmation. Among comorbidities, diabetes mellitus (DM) has been associated with an increased risk of HCC in several cohorts,<sup>22,26,31,36,37</sup> Abe et al incorporated DM status in a multivariable HCC risk score (see below) (Table 7). Other factors such as alcohol consumption,<sup>21,41</sup> and viral co-infections<sup>11</sup> are likely to influence post-SVR

HCC risk, although these patients were systematically excluded from most clinical trials.

#### Genetic Predictors

A single-center study conducted in a large cohort of DAA-treated cirrhotic patients found that a genetic risk score combining 4 single nucleotide polymorphisms (SNPs) [PNPLA3, TM6SF2, MBOAT7 and GCKR] was an independent predictor of de-novo HCC, together with other clinical predictors (DM, male gender, albumin values)<sup>31</sup> (Tables 3 and 6). The same authors found that the toll-like 1 (TLL1) gene, which had been previously associated with HCC occurrence in Japanese CHC patients,<sup>47</sup> did not predict de-novo HCC in 348 European cirrhotics.<sup>26</sup>

#### Virus-Related Factors

Two studies, only, reported that HCV genotype might influence the risk of HCC during follow-up. Nahon et al found that HCV-1 patients were at increased risk of HCC development,<sup>21</sup> whilst genotype 3 was independently associated with de-novo HCC in a large retrospective study from US<sup>41</sup> (Table 3).

#### Alpha-Fetoprotein ( $\alpha$ FP)

Although not universally recommended for HCC surveillance by international guidelines due to its low sensitivity and specificity, broad application of  $\alpha$ FP in routine clinical practice has led many authors to investigate its potential for de-novo HCC prediction.  $\alpha$ FP was independently associated with HCC occurrence, either in patients with cirrhosis<sup>32,38,42</sup> or advanced fibrosis.<sup>44</sup> Some studies evaluated the predictive ability of  $\alpha$ FP assessed at baseline,<sup>32,42,44</sup> while others analysed the EOT time-point.<sup>38</sup> Most studies tried to identify a predictive  $\alpha$ FP cut-off: overall, the proposed cut-offs resulted always higher than the reference standard 7 ng/mL (ie, >9 or  $\geq 10$  ng/mL, >20 mg/mL)<sup>38,42,44</sup> (Tables 3 and 6).

#### Undefined Nodules

Sangiovanni et al found that the presence of undefined/non-malignant nodules at baseline was an independent predictor of HCC occurrence in cirrhotic patients.<sup>32</sup> Partially in line with this finding is what reported by Tamaki et al, as they found that Li-Rads 3/4 nodules were independently associated with HCC occurrence in CHC patients (6.9% cirrhotics).<sup>48</sup> To avoid biases related to inclusion of patients carrying nodules at risk of HCC transformation, presence of undefined nodules was declared to be an exclusion criterion in some studies<sup>10,22,26,31,36</sup> (Table 3).



### Lack of a Sustained Virological Response

Some studies including large cohorts of treated patients did not allow separate analysis of those achieving an SVR, thus leading to include non-SVR among potential predictors of de-novo HCC. Although the statistical power when analysing the influence of non-SVR status on HCC risk, some authors reported that the lack of an SVR was associated to increased HCC occurrence<sup>20,28,34,35,39</sup> (Table 3).

### Combined Predictors and HCC Risk Scores

The risk of de-novo HCC increased when two or more independent predictors identified at multivariable analysis were combined. Not surprisingly, in all cases HCC cumulative incidences (CumI) proportionally increased according to the number of risk factors considered.<sup>11,20,22,28,46</sup> These studies mostly included parameters associated with liver disease severity (LSM, APRI, CPT score, PLT, albumin), DM and SVR status. Conversely, other studies evaluated composite HCC risk scores, which were based on combinations of multiple variables, to stratify patients into different HCC-risk classes. Four studies focused only on patients with advanced fibrosis or cirrhosis, by proposing a combination of patient-related (age, gender, presence of DM) and biochemical variables (albumin,  $\gamma$ GT, PLT,  $\alpha$ FP) together with data related to liver disease severity.<sup>33,37,44,45</sup> The aMAP score failed in predicting de-novo HCC in 2085 F3-F4 patients with HCV-4,<sup>49</sup> and, similarly, GES score performance was suboptimal in a Caucasian cohort.<sup>30</sup> Cumulative incidences of de-novo HCC according to different risk classes are reported in Table 7.

### Studies Enrolling Patients with Chronic Hepatitis C (Any Fibrosis Stage)

Twenty-three studies reported data on HCC occurrence in CHC patients with any stage of liver fibrosis (Table 3). Almost all these studies included cirrhotic patients; rates of cirrhotics ranged between 6% and 73%, although some authors did not provide this information. Most studies included only patients with an SVR, whilst data could be extrapolated from three studies.<sup>34,42,50</sup> In studies including non-SVR patients, treatment failure accounted for 3.0–6.7% of DAA treatment responses (Table 4).

Overall, 0.9% to 6.9% of CHC patients developed de-novo HCC during follow-up, although only few authors reported the prevalence of cirrhosis in CHC cohorts. When reported, rates of cirrhosis were between 38% and 100% in

CHC patients developing HCC<sup>35,39,40,51–53</sup> (Table 4), and overall CumI of de-novo HCC were lower than that reported in cirrhotic cohorts, at each time-point (Tables 2 and 4).

### Severity of Liver Disease

Due to the inclusion of cirrhotic patients in CHC cohorts, liver disease severity was independently associated with HCC occurrence in most studies. Only 5 studies were able to identify HCC predictors in non-cirrhotic F0-F3 patients,<sup>34,37,38,40,42</sup> and three of them included indirect markers of fibrosis, either biochemical tests or NITs (see below) (Table 5).

### Cirrhosis and Advanced Fibrosis

Whatever defined, cirrhosis and advanced fibrosis were independently associated with HCC development in several studies.<sup>34,38,39,54,55</sup> In these studies, cirrhosis was differently defined (Table 1), and ranged between 18% and 56% of the overall population. Particularly, the CHC cohort described by Pinero et al included 399 (29%) patients with clinically significant portal hypertension (CSPH) (Table 4).

### Liver Stiffness Measurement

Baseline LSM obtained by Acoustic Radiation Force Impulse (ARFI) or TE, was associated with an increased risk of post-treatment HCC (Table 5) in three studies analysing SVR patients.<sup>53,56,57</sup> Tachi et al identified the 1.73 m/s threshold as the optimal cut-off to stratify CHC patients according to their de-novo HCC risk<sup>56</sup> (Table 5). In the other two studies, baseline LSM  $\geq 20$  kPa and  $\geq 17.5$  kPa were associated with HCC occurrence in 398 and 773 CHC patients from Japan and Denmark, respectively. In both studies, the prevalence of cirrhosis was not reported.<sup>53,57</sup> Ogasawara et al reported that also SVR24-LSM (ie, LSM performed 24 weeks after EOT)  $\geq 10$  kPa was independently associated with de-novo HCC.<sup>57</sup> This finding was in line with two other Japanese studies, identifying in LSM  $\geq 3.75$  kPa obtained through Magnetic Resonance Elastography (MRE) 12 weeks after treatment completion (SVR12-MRE) an independent predictor of HCC occurrence.<sup>48,58</sup>

### Serological Non-Invasive Tests

Most studies reported that either baseline or post-treatment FIB-4 values were associated with the risk of de-novo HCC in CHC patients. In 5 studies, baseline FIB-4 was

reported to be an independent risk factor for HCC occurrence.<sup>34,40,47,50,59</sup> Risk thresholds varied according to each study: Kanwal et al used the standard 3.25 cut-off,<sup>34</sup> whereas Iio et al used the 2.67 cut-off.<sup>47</sup> In the study by Watanabe et al, baseline FIB-4 predicted HCC in females, only.<sup>59</sup> In addition, three Japanese studies reported that post-SVR FIB-4 (at EOT and at SVR12) and changes in FIB-4 independently predicted de-novo HCC.<sup>50,55,60</sup> Among investigated serological biomarkers of fibrosis was *Wisteria floribunda* agglutinin positive Mac-2 (WFA\*M2BP), which was tested in the study by Nagata et al, reporting that WFA\*M2BP assessed 24 weeks after EOT independently predicted de-novo HCC<sup>55</sup> (Tables 5 and 6).

#### Biochemical Surrogates of Advanced Liver Disease

Albumin and PLT were independently associated with HCC occurrence in two studies reporting data on F0-F3 patients.<sup>37,38</sup> Also, Watanabe et al found that low pre-treatment albumin values (<3.8 g/dl) increased the risk of HCC<sup>49</sup> (Tables 5–7).

#### Patient-Related Factors

Male gender and age independently predicted HCC occurrence also in CHC cohorts. Male gender was associated with de-novo HCC in 5<sup>40,50,55,59,60</sup> studies, and age in 7<sup>40,41,48,52,53,55,58</sup> (Table 5). Although age was analysed as a continuous variable in multivariate analysis, different cut-offs were associated with increased risks of HCC (>60, >62, >75 years). Race still emerged as independent predictor of de-novo HCC in the large US cohorts,<sup>34,41</sup> but was not confirmed by other studies. Co-morbidities influenced HCC development also in CHC cohorts: Kanwal et al reported that the presence of DM was independently associated with HCC occurrence,<sup>34</sup> whereas other studies found that altered  $\gamma$ GT and ALT values predicted post-SVR HCC,<sup>40,55</sup> likely mirroring the presence of underlying metabolic disorders (Tables 5 and 6).

#### Genetic Predictors

In CHC patients, two genetic factors were independently associated with HCC occurrence. Nagata et al found that IL28B rs8099917 polymorphism (non-TT) was associated with an increased risk of HCC in a large cohort of 752 patients followed-up for 1.8 years.<sup>54</sup> Conversely, the Japanese study by Iio et al reported that patients carrying the TLL1 rs17047200 AT/TT genotypes had significantly higher CumI of HCC, although T allele was associated

with lower PLT and higher FIB-4 values.<sup>47</sup> In 348 F0-F3 patients from Italy, TLL1 genotype did influence HCC risk<sup>26</sup> (Table 5).

#### Alpha-Fetoprotein

Baseline  $\alpha$ FP was independently associated with de-novo HCC in 4 studies, which however identified different cut-offs: >4.6 ng/mL  $\geq$ 8 ng/mL and  $\geq$ 10 ng/mL<sup>42,47,55,57</sup> (Table 5). In addition, some authors investigated the predictive values of post-treatment  $\alpha$ FP (Table 5): values at both EOT,<sup>50–52,59</sup> and SVR12<sup>48,58,60</sup> time-points were associated with de-novo HCC. At SVR12, the following cut-offs were identified: >5 ng/mL, >6.5 ng/mL,  $\geq$ 6 ng/mL. Interestingly, Watanabe et al proposed two different cut-offs (ROC analysis) for post-treatment  $\alpha$ FP according to patient gender: >6.0 ng/mL in females and >3.5 ng/mL in males, respectively<sup>59</sup> (Tables 5 and 6).

#### Virus-Related Factors

The only study reporting a role of virus-related factors is the one by Kanwal et al, finding an association between HCV genotype 3 and de-novo HCC.<sup>41</sup>

#### Combined Scores

In the setting of CHC patients, 4 studies developed scores based on multiple variables to predict de-novo HCC, mostly assessed at EOT or SVR time-points. Hiraoka et al proposed the ADRES score, based on the combination of gender, FIB-4 and  $\alpha$ FP assessed at SVR24, while Tani et al incorporated EOT- $\alpha$ FP (>6 ng/mL) and age (>75 years)<sup>52,60</sup> (Table 7). Iio et al combined SVR24-  $\alpha$ FP and FIB-4 with the TLL1 genotype,<sup>47</sup> while Watanabe et al proposed two different models, either pre-DAA (including FIB-4, albumin and gender) or post-DAA (incorporating EOT- FIB-4 and  $\alpha$ FP values)<sup>50</sup> (Table 7).

#### Predictors of Recurrent HCC

The risk of HCC following antiviral treatment was strongly influenced by previous HCC history. Not only rates of recurrent HCC were significantly higher than those of de-novo HCC (Tables 2, 4, 5 and 8), but previous HCC history was the strongest predictor of HCC development in cohorts analysing cumulative data from patients with and without pre-DAA liver cancer. Rates of HCC recurrence following DAA were similar<sup>18,19,23,61</sup> or even lower<sup>62</sup> than those reported in untreated patients, and most authors reported that oral antivirals did not enhance the risk of recurrence.<sup>12,15,18,19,23,61</sup>

**Table 8** Characteristics of Studies Reporting Data on HCC Recurrence

Author	Enrollment Period	Study Design	Patients	Males	Age	Fibrosis	CPT Score	SVR	HCC (Number)	Follow-Up
<b>Cirrhosis (n=12)</b>										
Conti, 2016 <sup>8</sup>	Italy 2015	Multicenter, retrospective	59	40 (68%)	72 (48–84)	LSM 23.6 ± 1.39	CPT-A 49 CPT-B 10	53 (90%)	17 (29%) SVR 15 CPT-A 12	24 <sup>oo</sup>
Pol, 2016 <sup>23</sup>	France 2012–2014	Multicenter, retrospective,	13 (CIR/IR)	11 (85%)	61 ± 10	NA	CPT-A 13*	13 (100%)	1 (7.7%)	16.5 (12.7–32.2) m
Zavaglia, 2017 <sup>72</sup>	Italy	Multicenter, retrospective	31	20 (65%)	65 ± 8	NA	CPT-A 25 CPT-B 6	26/27 (96.3%)	1 (3.2%)	8 (P25-P75:5–10.9) <sup>o</sup> m
Virlogeux, 2017 <sup>61</sup>	France 2009–2016	Single-center retrospective,	23	20 (87%)	58 (51–84)	NA	CPT-A 20 CPT-B 3	22 (96%)	11 (47.8%) CPT-A 9	NA
Cabibbo, 2017 <sup>13</sup>	Italy 2015–2016	Multicenter, prospective	143	86 (60%)	70 ± 9	NA	CPT-A 123 CPT-B 20	138 (96%)	29 (20.3%)	8.7 (3–19) <sup>oo</sup> m
Ravaioli, 2018 <sup>25</sup>	Italy 2015–2016	Single-center, retrospective	19	NA	NA	NA	NA	NA	7 (36.8%)	15 (12–19) <sup>o</sup> m
Degasperi, 2019 <sup>22</sup>	Italy 2014–2016	Single-center, longitudinal	60	37 (62%)	72 (51–86)	LSM 24.4 (13.1–33.3)	CPT-A 52 CPT-B 8	97% <sup>o</sup>	20 (33%) SVR 19	25 (3–39) <sup>o</sup> m
Lleo, 2019 <sup>28</sup>	Italy 2015	Multicenter, longitudinal	161	111 (70%)	151 (94%) ≥50years	53 (33%) LSM ≥25 kPa	CPT-A 137 CPT-B/C 22	153 (95%)	38 (23.6%) SVR 34 CPT-A 35	NA
Kwon, 2019 <sup>51</sup>	Korea 2015–2017		28	NA	NA	NA	NA	22/24 (91.7%)	5 (17.9%) SVR 5	1y <sup>oo</sup> m
Casadei-Gardini, 2019 <sup>29</sup>	Italy 2015–2016	Multicenter, Retrospective	98	60 (61.2%)	71 (47–86)	NA	CPT-A 72 CPT-B 26	NA	30 (30.6%)	18.0 (0.4–26.4) m <sup>o</sup>
Degasperi, 2020 <sup>31</sup>	Italy 2014–2016	Single-center, retrospective	57	36 (63%)	72 (51–86)	LSM 21.0 (12.0–36.3) FIB-4 6.0 (1.1–22.4)	CPT-A 49 CPT-B 8	96% <sup>o</sup>	28 (49%) CPT-A 25	43 (3–57) <sup>o</sup> m

(Continued)

Table 8 (Continued).

	Italy	Multicenter, prospective	124	85 (69%)	73 (46–86)	NA	CPT-A 112 CPT-B 12	118 (95%)	40 (32%) SVR 36	16 (5–31) m°
<b>Any Fibrosis Stage or not specified (n=12)</b>										
Sangiovanni, 2020 <sup>32</sup>	Spain 2014–2015	Multicenter, retrospective	58	40 (69%)	66 (45–83)	NA	55 (95%) (CPT-A 50) (CPT-B 3) (CPT-C 2)	39/40 (97.5%)	16 (27.6%) F4 15 CPT-A 11 CPT-B 2 CPT-C 1	5.7 (0.4–14.6) m°°
Torres, 2016 <sup>63</sup>	US 2010–2015	Single-center prospective	8	7 (88%)	64 (57–87)	NA	7 (88%) (CPT-A 3) (CPT-B 4)	6 (75%)	0	12 (4–60) m°°
Poi, 2016 <sup>23</sup>	France 2012–2014	Multicenter, retrospective	189 (HEPATHER)	147 (78%)	62 ± 9	NA	152 (80%)	148 (91.9%)	24 (12.7%)	20.2 m°
Kolly, 2017 <sup>64</sup>	Europe	Multicenter, retrospective	47	76%	60 (48–78)	NA	40 (85%) CPT-A 80%	NA	NA	9.6 m°°
Tachi, 2017 <sup>56</sup>	Japan 2014–2015	Multicenter, prospective	30	NA	NA	NA	NA	30 (100%)	12 (40%)	18.1 (5.6–31.2) m°
Ikeda, 2017 <sup>62</sup>	Japan 2014–2016	Single-center, retrospective	177	106 (60%)	71 (39–87)	NA	NA	155/173 (90%)	61 (34.5%)	20.7 (7.0–26.2) m°
Nagata, 2017 <sup>54</sup>	Japan 2014–2017	Multicenter, retrospective	83	NA	NA	NA	NA	NA	22 (27%)	2.3 y
Ogawa, 2018 <sup>38</sup>	Japan 2015–2016	Multicenter	152	81 (53%)	74 (66–79)	NA	90 (59%) CPT-A 100%	152 (100%)	26 (17%)	17 (1–23) m°°
Kogiso, 2018 <sup>65</sup>	Japan 2014–2018	Single-center retrospective	45	32 (71%)	69 (48–82)	FIB-4 5.33 (1.64–15.40)	15 (33%) CPT A5-B8	43 (96%)	15 (33%) SVR 14 F4 15	25.9 (2.7–41.3) m°

Nakano, 2019 <sup>66</sup>	Japan 2015–2017	Multicenter	459	269 (59%)	75 ± 8	FIB-4 7.10 ± 4.16 APRI 2.32 ± 1.81	323 (70%)	459 (100%)	217 (47.2%)	29.4 ± 6.8 m°
Zou, 2019 <sup>67</sup>	US 2015–2017	Multicenter, retrospective	264	261 (99%)	66 ± 5	NA	222 (84%) CPT-A 172 CPT-B 46 CPT-C 4	244 (92%)	69 (26.1%)  F4 69	23.3 (±9.9) m°
Ahn, 2020 <sup>68</sup>	South Korea 2015–2016	Multicenter, retrospective	100	67 (67%)	69 ± 8	NA	79 (79%) (CPT-A 74) (CPT-B 4) (CPT-C 1)	88 (88%)	37 (37%) F4 32  CPT-A 35 CPT-B 1 CPT-C 1	15.8 (4.4–29.9) m°

**Notes:** Values are expressed as median (range), mean ± standard deviation and/or percentages (%). Age is calculated in years-old; LSM is calculated in kPa. LSM by FibroScan®. From DAA start; \*\*From EOT. \*Only CPT-A patients included. †Available for patients with and without HCC history.

**Abbreviations:** HCC, hepatocellular carcinoma; F4, cirrhosis; SVR, sustained virological response; LSM, liver stiffness measurement; CPT, Child-Pugh-Turcotte score; w, weeks; m, months; y, years; P, percentile; FIB-4, fibrosis-4 index; APRI, AST to platelet ratio index; US, United States.

Rates of HCC recurrence ranged between 3.2% and 49%, with one study only<sup>63</sup> reporting no recurrence however among 8 patients (7 with cirrhosis) (Table 8). Almost all studies tried to identify clinical predictors of HCC recurrence during variable follow-up, despite the inclusion of patients with different characteristics, including tumour burden (Tables 8 and 9). In two retrospective French studies, the authors found HCC predictors different from DAA use when comparing untreated vs DAA-treated patients.<sup>23,61</sup> Similarly, Ogawa et al were not able to identify predictive factors of HCC recurrence in 62 F0-F3 patients with an SVR, whilst other studies on CHC patients did not focus on the sub-group of non-cirrhotics.<sup>38</sup> In most cases, data were obtained from cohorts including both SVR and non-SVR patients; 4 studies enrolled only cured patients, whilst this information was lacking in other 4. When reported, rates of treatment failure ranged between 2.5% and 25% (Table 8). In 12 studies all patients had a diagnosis of cirrhosis, and most of them (n=9) included also decompensated (CPT-B) patients (Table 8). In studies enrolling CHC patients, rates of cirrhosis ranged between 33% and 95% (n=9) or were not reported (n=4), and only few authors (n=4) reported information on fibrosis stage in patients with a complete response (CR) to previous HCC who subsequently developed HCC recurrence (Table 8).

### Severity of Liver Disease

Despite the inclusion of cirrhotic patients in CHC studies, only one of them was able to identify cirrhosis as an independent risk factor for HCC recurrence.<sup>38</sup> Although not reported in most cases, expected high rates of cirrhosis in patients developing recurrent HCC might have attenuated the weight of this variable. However, further reinforcing the strength of liver disease severity as HCC predictor, some authors found that indirect markers of fibrosis were independently associated with HCC recurrence. For example, Conti et al reported that baseline LSM independently predicted HCC in 59 cirrhotics followed-up for 24 weeks,<sup>8</sup> whereas Nagata et al found that WFA\*M2BP assessed at SVR24 predicted HCC recurrence in 83 CHC patients<sup>54</sup> (Table 9).

### Patient-Related Factors

According to published studies, patients' characteristics had low impact on HCC recurrence, as only few authors found that they were independently associated with recurrent HCC following an SVR to DAA. However, both age<sup>8,64</sup> and, in

cirrhotic patients, comorbidities such as DM<sup>22,31</sup> and alcohol<sup>32</sup> seemed to play a role in influencing HCC risk. Moreover, Degasperis et al reported that ethnicity (ie, Egyptian vs Italian) was an independent risk factor for HCC recurrence in their European cohort<sup>22</sup> (Tables 6 and 9).

### Tumour Burden

Rates of HCC recurrence were strongly influenced by tumour burden in most studies analysing either F4 or CHC cohorts (Table 9). One of the most important predictors of HCC recurrence was history of HCC recurrence before DAA<sup>8,13,32</sup> together with the number of HCC treatments finally leading to CR achievement before anti-HCV therapies.<sup>62,65,66</sup> In addition, time elapsing between prior HCC treatment and DAA start was significantly associated with an increased risk of recurrent HCC in several studies,<sup>38,64,67,68</sup> where patients treated for HCC less than one year prior to DAA exhibited an increased risk of tumour recurrence.<sup>38,68</sup> Lastly, some authors reported that also prior HCC size,<sup>13</sup> number of nodules<sup>38</sup> and type of HCC treatment (ie, palliative vs curative)<sup>38,67</sup> were independently associated with HCC recurrence, although these data were not confirmed by others<sup>8,22,65</sup> (Table 6). However, these results should be cautiously interpreted, as they are strongly influenced by study design and patients enrollment; recently, an individual patient-data meta-analysis pooling data of 977 patients from 21 studies have further enhanced the importance of pre-DAA HCC history and tumour burden.<sup>19</sup>

### HCC Biomarkers

Four studies found that higher baseline (DAA start) values of  $\alpha$ FP were independently associated with HCC recurrence.<sup>19,28,54,66</sup> Casadei-Gardini and others found that aspartate aminotransferase to lymphocyte ratio (ALRI), which had been previously proposed for inclusion in HCC surveillance algorithms,<sup>69</sup> independently predicted HCC recurrence in 98 cirrhotic patients (73% CPT-A) treated with DAA 8.5 months after CR<sup>29</sup> (Tables 6 and 9).

### Conclusions

Despite the expected decrease in HCC burden,<sup>70</sup> the widespread use of DAA to cure HCV infection will finally lead large cohorts of SVR patients to be maintained under surveillance. In fact, the number of patients requiring HCC surveillance due to pre-treatment advanced fibrosis is expected to increase over time, as a consequence of worldwide diffusion of HCV screening and treatment programs.<sup>71</sup> Therefore, we are going to face with larger, ageing population still at risk of

**Table 9** Incidence and Factors Associated with HCC Recurrence

Author	SVR Status	Incidence of HCC (Cuml)						Independent Predictors	Time to HCC Recurrence (From DAA)
		Cuml							
		6-Month	1-Year	1.5-Year	2-Year	3-Year	4-Year		
<b>Cirrhosis (n=11)</b>									
Conti, 2016 <sup>8</sup>	SVR + non-SVR	3.1%	-	-	-	-	-	Age, LSM	NA
Pol, 2016 <sup>23</sup>	SVR	-	-	-	-	-	1.11 PM	-	16.5 (12.7-32.2) m
Zavaglia, 2017 <sup>22</sup>	SVR + non-SVR	-	-	-	-	-	-	NA	8 m
Virlogeux, 2017 <sup>61</sup>	SVR + non-SVR	-	-	-	-	-	1.7 PM	None***	13.0 (3.0-24.7) m <sup>o</sup>
Cabibbo, 2017 <sup>13</sup>	SVR + non-SVR	12%	26.6%	29.1%	-	-	-	HCC size, prior HCC recurrence	NA
Ravaioli, 2018 <sup>25</sup>	SVR + non-SVR	-	-	-	-	-	-	NA	10 (6-15) <sup>oo</sup>
Degasperi, 2019 <sup>22</sup>	SVR + non-SVR	7.0%	17%	27%	43%	43%	-	DM	23 (7-37) m <sup>o</sup>
Lleo, 2019 <sup>28</sup>	SVR + non-SVR	8.5%	20.9%	26.9%	-	-	-	Non-SVR, $\alpha$ FP $\geq$ 10 ng/mL	NA
Casadei-Gardini, 2019 <sup>29</sup>	SVR + non-SVR	0.074*	0.261*	0.380*	-	-	-	ALRI	19.2 (1.1-26.44) m <sup>o</sup>
Degasperi, 2020 <sup>31</sup>	SVR + non-SVR	-	-	-	-	-	51%	DM, ethnicity	NA
Sangiovanni, 2020 <sup>32</sup>	SVR + non-SVR	-	-	-	42.9%	-	29.9	Alcohol, prior HCC recurrence	NA
<b>Any Fibrosis Stage or not specified (n=10)</b>									
Reig, 2016 <sup>7</sup>	SVR + non-SVR	-	-	-	-	-	-	NA	3.5 (1.1-8) m <sup>o</sup>
Pol, 2016 <sup>23</sup>	SVR + non-SVR	-	-	-	-	-	0.73 PM	None***	NA

(Continued)

**Table 9 (Continued).**

Kelly, 2017 <sup>64</sup>	NA	4%	19%	-	42%	-	-	-	Age, time HCC Tx-DAA	NA
Ikeda, 2017 <sup>62</sup>	SVR + non-SVR**	9.6**	30.1%**	-	39.6%**	-	-	-	Number of prior HCC Tx	NA
Nagata, 2017 <sup>54</sup>	SVR + non-SVR**	-	-	-	-	22.9%**	-	-	<b>Pre-DAA:</b> αFP <b>SVR24:</b> WFA*†M2BP**	2.3 y
Ogawa, 2018 <sup>38</sup>		-	<b>Overall</b> NA <b>F0-F3</b> 6.5% <b>F4</b> 23.1%	-	-	-	-	-	<b>Overall:</b> Cirrhosis, time HCC Tx-DAA <1 year, nodules ≥2, palliative HCC Tx <b>F0-F3:</b> None <b>F4:</b> Time HCC Tx-DAA <1 year, palliative HCC Tx	NA
Kogiso, 2018 <sup>65</sup>	SVR	-	-	-	-	-	-	-	Number of prior HCC Tx	11.6 (2.2-34.2) m**
Nakano, 2019 <sup>66</sup>	SVR	-	27.1%	-	43.6%	51.1%	-	-	αFP; number of prior HCC Tx	34 m***
Zou, 2019 <sup>67</sup>	SVR + non-SVR	-	3.3%	-	20.3%	-	-	3.8	Palliative HCC Tx, Time HCC Tx-DAA, non-SVR	12.2 ± 8 m*
Ahn, 2020 <sup>68</sup>	SVR + non-SVR	-	28.4%	-	61.3%	-	-	-	Last HCC Tx <1 year	NA

**Notes:** \*From DAA start; \*\*From EOT; \*\*\*From SVR 12. \*Cumulative Hazards of HCC recurrence; \*\*Cuml are available for SVR patients, only (vs predictors of HCC); \*\*\*comparison between untreated vs DAA-treated CR patients. **Abbreviations:** HCC, hepatocellular carcinoma; Cuml, cumulative incidence; DAA, direct-acting antivirals; LSM, liver stiffness measurement; F4, cirrhosis; CHC, chronic hepatitis C; NA, not available; PM, person/month; w, weeks, m, months; y, years; ALRI, AST to lymphocyte ratio; αFP, alpha-fetoprotein; DM, diabetes mellitus; WFA\*†M2BP, *Wisteria floribunda* agglutinin positive Mac-2 binding protein; tx, treatment; DAA, direct-acting antivirals; CR, complete response.



HCC, although HCC risk is lower than that reported in active HCV infection. As a consequence, the investigation of HCC predictors is of paramount importance in order to better optimize surveillance strategies, with the ultimate goal of personalized follow-up algorithms. While advanced fibrosis and cirrhosis represent strong predictors of HCC development, either de-novo or recurrent, literature data suggest that many co-factors may contribute to the oncogenic risk. While some of these factors are modifiable or can be potentially improved by successful antiviral treatments (fibrosis, portal hypertension), others are only partially modifiable (metabolic syndrome) or not modifiable at all (aging, HCC history). Due to the complex interactions and competing risks resulting from these variables, combination analyses or composite scores are those expected to better improve prediction capability, with all the challenges related to large-scale applicability in heterogeneous patient populations. Therefore, in most cases prospective validation in larger cohorts is still needed.

## Disclosure

Roberta D'Ambrosio reports being on the advisory board for AbbVie and MSD; speaking and teaching for AbbVie, Gilead and MSD; and research support from AbbVie, Gilead and MSD, outside the submitted work. Elisabetta Degaspero reports personal fees from ABBVIE and grants, personal fees and non-financial support from GILEAD, outside the submitted work. The authors report no conflicts of interest in this work.

## References

- European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol.* 2018;69:182–236.
- Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. *Nat Rev Dis Primers.* 2021;7(1):6. doi:10.1038/s41572-020-00240-3
- Van der Meer A, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA.* 2012;308:2584–2593. doi:10.1001/jama.2012.144878
- Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Ann Intern Med.* 2013;158:329–337. doi:10.7326/0003-4819-158-5-201303050-00005
- El-Serag HB, Kanwal F, Richardson P, et al. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C infection. *Hepatology.* 2016;64:130–137. doi:10.1002/hep.28535
- van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. *J Hepatol.* 2017;66:485–493. doi:10.1016/j.jhep.2016.10.017
- Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumour recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol.* 2016;65:719–726. doi:10.1016/j.jhep.2016.04.008
- Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *H Hepatol.* 2016;65:727–733. doi:10.1016/j.jhep.2016.06.015
- Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. *J Hepatol.* 2016;65:856–858. doi:10.1016/j.jhep.2016.06.009
- Cardoso H, Vale AM, Rodrigues S, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. *J Hepatol.* 2016;65:1070–1071. doi:10.1016/j.jhep.2016.07.027
- Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. *J Hepatol.* 2018;69:345–352. doi:10.1016/j.jhep.2018.03.009
- Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. *J Hepatol.* 2017;67:1204–1212. doi:10.1016/j.jhep.2017.07.025
- Cabibbo G, Petta S, Calvaruso V, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. *Aliment Pharmacol Ther.* 2017;46:688–695. doi:10.1111/apt.14256
- Ioannou G, Green P, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. *J Hepatol.* 2018;68:25–32. doi:10.1016/j.jhep.2017.08.030
- Saraiya N, Yopp AC, Rich NE, et al. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. *Aliment Pharmacol Ther.* 2018;48:127–137. doi:10.1111/apt.14823
- Guarino M, Viganò L, Ponziani FR, et al. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: literature review and risk analysis. *Dig Liver Dis.* 2018;50:1105–1114. doi:10.1016/j.dld.2018.08.001
- Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. *Gastroenterology.* 2019;157:1264–1278. doi:10.1053/j.gastro.2019.07.033
- Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American Cohort Study. *Gastroenterology.* 2019;156:1683–1692. doi:10.1053/j.gastro.2019.01.027
- Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut.* 2021;gutjnl-2020-323663. doi:10.1136/gutjnl-2020-323663
- Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. *Gastroenterology.* 2018;155:411–421. doi:10.1053/j.gastro.2018.04.008
- Nahon P, Layese R, Bourcier V, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. *Gastroenterology.* 2018;155:1436–1450. doi:10.1053/j.gastro.2018.07.015
- Degaspero E, D'Ambrosio R, Iavarone M, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. *Clin Gastroenterol Hepatol.* 2019;17:1183–1191. doi:10.1016/j.cgh.2018.10.038
- ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. *J Hepatol.* 2016;65:734–740. doi:10.1016/j.jhep.2016.05.045

24. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. *J Hepatol.* 2020;73:1170–1218.
25. Ravaioli F, Conti F, Brillanti S, et al. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variation in HCV cirrhotics treated with direct acting antivirals. *Dig Liv Dis.* 2018;50:573–579. doi:10.1016/j.dld.2018.02.010
26. Degasperi E, Galmozzi E, Facchetti F, et al. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals. *J Viral Hepat.* 2019;26:1233–1236. doi:10.1111/jvh.13155
27. Rinaldi L, Guarino M, Perrella A, et al. Role of liver stiffness measurement in predicting HCC occurrence in direct-acting antivirals setting: a real-life experience. *Dig Dis Sci.* 2019;64:3013–3019. doi:10.1007/s10620-019-05604-8
28. Lleo A, Aglitti A, Aghemo A, et al. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. *Dig Liv Dis.* 2019;51:310–317. doi:10.1016/j.dld.2018.10.014
29. Casadei Gardini A, Foschi FG, Conti F, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. *Dig Liver Dis.* 2019;51:681–688. doi:10.1016/j.dld.2018.09.016
30. Bergna I, Degasperi E, D'Ambrosio R. Suboptimal accuracy of GES score to stratify post-SVR HCC risk in a single center cohort of European cirrhotics infected with any HCV genotype. *Liver Int.* 2021;41:1152–1153. doi:10.1111/liv.14700
31. Degasperi E, Galmozzi E, Pelusi S, et al. Hepatic Fat-Genetic Risk score predicts hepatocellular carcinoma in cirrhotic patients treated with DAAs. *Hepatology.* 2020;72:1912–1923. doi:10.1002/hep.31500
32. Sangiovanni A, Alimenti E, Gattai R, et al. Undefined/non-malignant nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. *J Hepatol.* 2020;73:593–602. doi:10.1016/j.jhep.2020.03.030
33. Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis C. *J Hepatol.* 2020;73:1368–1378. doi:10.1016/j.jhep.2020.07.025
34. Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. *Gastroenterology.* 2017;153:996–1005. doi:10.1053/j.gastro.2017.06.012
35. Finkelmeier F, Dultz G, Peiffer KH, et al. Risk of de-novo hepatocellular carcinoma after HCV treatment with direct-acting antivirals. *Liver Cancer.* 2018;7:190–204. doi:10.1159/000486812
36. Rinaldi L, Perrella A, Guarino M, et al. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct-acting antivirals: a prospective multicenter study. *J Transl Med.* 2019;17:292. doi:10.1186/s12967-019-2033-x
37. Abe K, Wakabayashi H, Nakayama H, et al. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. *PLoS One.* 2020;15:e0243473. doi:10.1371/journal.pone.0243473
38. Ogawa E, Furusyo N, Nomura H, et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. *Aliment Pharmacol Ther.* 2018;47:104–113. doi:10.1111/apt.14380
39. Pinero F, Mendizabal M, Ridruejo E, et al. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. *Liver Int.* 2019;30:1033–1043. doi:10.1111/liv.14041
40. Ide T, Koga H, Nakano M, et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. *Hepatol Intern.* 2019;13:293–301. doi:10.1007/s12072-019-09939-2
41. Kanwal F, Kramer JR, Asch SM, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. *Hepatology.* 2020;71:44–55. doi:10.1002/hep.30823
42. Tanaka Y, Ogawa E, Huang CF, et al. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. *Hepatol Intern.* 2020;14:1023–1033. doi:10.1007/s12072-020-10105-2
43. de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol.* 2015;63:743–752. doi:10.1016/j.jhep.2015.05.022
44. Shiha G, Waked I, Soliman R, et al. GES: a validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals. *Liver Int.* 2020;40:2828–2833. doi:10.1111/liv.14666
45. Alonso Lopez S, Manzano ML, Gea F, et al. A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus – advanced fibrosis. *Hepatology.* 2020;72:1924–1934. doi:10.1002/hep.31588
46. Pons M, Rodriguez-Tajes S, Esteban JI, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. *J Hepatol.* 2020;72:472–480. doi:10.1016/j.jhep.2019.10.005
47. Iio E, Matsuura K, Shimada N, et al. TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy. *J Gastroenterol.* 2019;54:339–346. doi:10.1007/s00535-018-1526-3
48. Tamaki N, Higuchi M, Kurosaki M, et al. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. *J Viral Hepat.* 2019;26:893–899. doi:10.1111/jvh.13103
49. Shiha G, Mikhail N, Soliman R. External validation of aMAP risk score in chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs. *J Hepatol.* 2021;74:994–996. doi:10.1016/j.jhep.2020.10.008
50. Watanabe T, Tokumoto Y, Joko K, et al. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. *Hepatol Res.* 2019;49:136–146. doi:10.1111/hepr.13278
51. Kwon JH, Yoo SH, Nam SW, et al. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: a multicenter study in Korea. *J Med Virol.* 2019;91:1104–1111. doi:10.1002/jmv.25412
52. Tani J, Morishita A, Sakamoto T, et al. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: all Kagawa Liver Disease Group Study. *Oncol Lett.* 2020;19:2205–2212. doi:10.3892/ol.2020.11341
53. Søholm J, Hansen JF, Mossner B, et al. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurement below 17.5 kilopascal who achieve SVR following DAAs. *PLoS One.* 2020;15:e0243725. doi:10.1371/journal.pone.0243725
54. Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. *J Hepatol.* 2017;67:933–939. doi:10.1016/j.jhep.2017.05.028
55. Ogawa E, Nomura H, Nakamura M, et al. Development of hepatocellular carcinoma by patients aged 75–84 with chronic Hepatitis C treated with direct-acting antivirals. *J Infect Dis.* 2020;jiaa359. doi:10.1093/infdis/jiaa359
56. Tachi Y, Hirai T, Kojima Y, et al. Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals. *J Gastroenterol Hepatol.* 2017;1:44–49.
57. Ogasawara N, Saitoh S, Akuta N, et al. Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C. *Hepatol Res.* 2020;50:426–438. doi:10.1111/hepr.13467

58. Higuchi M, Tamaki N, Kurosaki M, et al. Prediction of hepatocellular carcinoma after sustained virological response using magnetic resonance elastography. *Clin Gastroenterol Hepatol*. 2019;17:2616–2618. doi:10.1016/j.cgh.2018.11.046
59. Watanabe T, Tokumoto Y, Joko K, et al. Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection. *J Med Virol*. 2020;92:3507–3515. doi:10.1002/jmv.25984
60. Hiraoka A, Kumada T, Ogawa C, et al. Proposed a simple score for recommendations of scheduled ultrasonography surveillance for hepatocellular carcinoma after direct acting antivirals: multicenter analysis. *J Gastroenterol Hepatol*. 2019;34:436–441. doi:10.1111/jgh.14378
61. Virlogeux V, Pradat P, Hartig-Lavie K, et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. *Liver Int*. 2017;37:1122–1127. doi:10.1111/liv.13456
62. Ikeda K, Kawamura Y, Kobayashi M, et al. Direct-acting antivirals decreases tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma. *Dig Dis Sci*. 2017;62:2932–2942. doi:10.1007/s10620-017-4739-z
63. Torres HA, Vauthey JN, Mahale P, et al. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment. *J Hepatol*. 2016;65:856–868. doi:10.1016/j.jhep.2016.05.034
64. Kolly P, Waidmann O, Vermehren J, et al. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a European multi-centre study. *J Hepatol*. 2017;67:876–888. doi:10.1016/j.jhep.2017.07.007
65. Kogiso T, Sagawa T, Kodama K, et al. Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virus. *JGH Open*. 2018;3:52–60. doi:10.1002/jgh3.12105
66. Nakano M, Koga H, Ide T, et al. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study. *Cancer Med*. 2019;8:2646–2653. doi:10.1002/cam4.2061
67. Zou WY, Choi K, Kramer JR, et al. Risk of hepatocellular cancer recurrence in Hepatitis C virus+ patients treated with direct-acting antiviral agents. *Dig Dis Sci*. 2019;64:3328–3336. doi:10.1007/s10620-019-05641-3
68. Ahn YH, Lee H, Kim DY, et al. Independent risk factors for hepatocellular carcinoma recurrence after direct-acting antiviral therapy in patients with chronic hepatitis C. *Gut Liver*. 2020. doi:10.5009/gnl20151
69. Jin J, Zhu P, Liao Y, et al. Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. *Oncotarget*. 2015;6:19217–19227. doi:10.18632/oncotarget.4265
70. Chhatwal J, Wang X, Ayer T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. *Hepatology*. 2016;64:1442–1450. doi:10.1002/hep.28571
71. World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: updated version; 2016. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK362924/>. Accessed June 5, 2021.
72. Zavaglia C, Okolicsanyi S, Cesarini L, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? *J Hepatol*. 2017;66:236–251. doi:10.1016/j.jhep.2016.08.016

## Journal of Hepatocellular Carcinoma

Dovepress

### Publish your work in this journal

The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal that offers a platform for the dissemination and study of clinical, translational and basic research findings in this rapidly developing field. Development in areas including, but not limited to, epidemiology, vaccination, hepatitis therapy, pathology

and molecular tumor classification and prognostication are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-hepatocellular-carcinoma-journal>